Harmony Biosciences EPS Estimate Jumps 7.5% to $4.00
Consensus 2026 EPS estimates for Harmony Biosciences increased from $3.72 to $4.00 over the past 60 days, a 7.5% rise reflecting stronger outlook for its sleep disorder treatments. HRMY shares have fallen 0.5% over the past year, while delivering an average 7.2% earnings surprise over the past four quarters.
1. EPS Estimate Revision
Over the past 60 days, analysts boosted Harmony Biosciences’ 2026 EPS forecast from $3.72 to $4.00, a 7.5% increase that underscores confidence in the company’s approved sleep disorder therapies. Harmony holds a top Zacks Rank #1, reflecting strong expectations for its product revenue growth.
2. Earnings Surprise Record
Harmony delivered earnings that beat consensus estimates in two of the last four quarters, achieving an average earnings surprise of 7.2%, indicating periods of outperformance but also variability in quarterly results.
3. Stock Performance Trends
HRMY shares have declined 0.5% over the past year, modestly underperforming peers despite upward earnings revisions, suggesting investors are awaiting more consistent top-line growth signals.